Document is current
Any future updates will be listed below
-
Authors
Karadeniz, Hazan https://orcid.org/0000-0003-4665-3421
Güler, Aslıhan Avanoğlu https://orcid.org/0000-0001-9866-9797
Atas, Nuh https://orcid.org/0000-0001-5880-4974
Satış, Hasan https://orcid.org/0000-0002-7605-1301
Salman, Reyhan Bilici https://orcid.org/0000-0002-0783-1072
Babaoglu, Hakan https://orcid.org/0000-0002-3728-0259
Tufan, Abdurrahman https://orcid.org/0000-0001-6244-9362
- License Information
-
More Information
Article History
Received: 22 June 2019
Accepted: 29 November 2019
First Online: 7 December 2019
Compliance with ethical standards
:
: AT is Consultant for: Novartis and Abdi Ibrahim, Speaker Bureau of: Novartis, Pfizer and UCB with no conflict related to this study. AT is editorial board member of two international journals and reviewer for 3 international journals and research funding bodies. None of the authors have conflict of interest and non-financial relationships with agencies promoting tofacitinib.
: Written informed consent was obtained from all subjects. Permissions was taken from regulatory agencies for off-label uses of drugs. For each patient, we applied for permission of use and shared our Patient files with Medical Devices Agency of the Turkish Ministry of Health. The Turkish Ministry of Health granted the compassionate use of tofacitinib for FMF patients with special permission.
